Dr. Mikael Dolsten Named to Agilent Board of Directors
September 23 2021 - 4:05PM
Business Wire
Pfizer executive brings strong scientific and
medical expertise to Agilent board
Agilent Technologies, Inc. (NYSE: A) today announced that Dr.
Mikael Dolsten, chief scientific officer and president, Worldwide
Research, Development and Medical, Pfizer Inc. has been elected to
Agilent’s board of directors, effective Sept. 21, 2021.
Dr. Dolsten brings 30 years of pharma experience to the Agilent
board. During his career, he has led teams that have selected more
than 150 candidate drugs entering human clinical studies for the
treatment or prevention of human disease and has been involved in
advancing more than 30 drugs and vaccines to approval. Most
recently, he co-led Pfizer’s recent collaboration with BioNTech to
develop COMIRNATY® (COVID-19 vaccine, mRNA).
“Mikael’s outstanding scientific, medical and research
background makes him a valuable addition to the Agilent board,”
said Mike McMullen, Agilent president and CEO. “His leadership in
small-molecule medicines, biotherapeutics, gene therapies and
vaccines will be a key asset for Agilent moving forward. We look
forward to working with Mikael and benefitting from his experience
in these strategically important areas.”
“We’re pleased to welcome Mikael to the Agilent board,” said Koh
Boon Hwee, chair of the Agilent board. “His deep background in
pharma and successful leadership of critical research initiatives
at Pfizer will add an important perspective to our work at
Agilent.”
Dr. Dolsten has served in a variety of roles for Pfizer since
2009 including chief scientific officer, president of R&D and
senior vice president and division president, Biotherapeutics
Research and Development. He has served in his current role as
president of Worldwide Research, Development and Medical since
2019, where he leads a team of over 8,000 scientists and oversees
all global research operations across six therapeutic areas for
Pfizer. In addition, during his career, Dr. Dolsten has served in
research leadership positions for Wyeth Pharmaceuticals, Boehringer
Ingelheim, AstraZeneca and Pharmacia & Upjohn.
He has published more than 150 scientific articles and book
reviews and is an active leader in the scientific community. He
currently serves as co-chair of the National Institutes of Health
(NIH)-Accelerating Medicines Partnership program and an executive
committee member of the NIH Accelerating COVID-19 Therapeutic
Interventions and Vaccines (ACTIV) initiative coordinating a
national science strategy in response to COVID-19. Dr. Dolsten also
serves on the Science and Regulatory Executive Committee of the
Pharmaceutical Research and Manufacturers of America (PhRMA) and
the PhRMA Foundation Board of Directors. He has been an industry
member of the Government-University-Industry Research Roundtable
(GUIRR) Council and was recently elected as Foreign Member of The
Royal Swedish Academy of Engineering Sciences.
Dr. Dolsten has served as an advisor to the Obama administration
for regulatory sciences, to then Vice President Joe Biden in the
Cancer Moonshot initiative and to the UK Government for the 2021 G7
Summit.
He is a member of the board of directors for Karyopharm
Therapeutics, as well as the board at Vimian Group.
Dr. Dolsten received both his medical degree and doctorate from
Lund University in Sweden where he was also selected as an adjunct
professor in immunology.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets, delivering
insight and innovation toward improving the quality of life.
Agilent instruments, software, services, solutions, and people
provide trusted answers to customers' most challenging questions.
The company generated revenue of $5.34 billion in fiscal year 2020
and employs 16,400 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
please subscribe to the Agilent Newsroom. Follow Agilent on
LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210923005875/en/
Tom Beermann +1 408 386 5892 tom.beermann@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024